NCT06962488Recruiting
Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure
Clinical Implementation of Blood Pressure Polygenic Risk Score
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
In a multi-ethnic population, a genome-wide polygenic risk score (PRS) for systolic blood pressure (SBP), incorporating over one million common genetic variants, predicts blood pressure (BP) traits and the risk of adverse cardiovascular events beyond traditional risk factors. Delivering SBP PRS information to young and middle-aged adults with hypertension (HTN) and poor cardiovascular health (CVH) may enhance their motivation to adopt healthier lifestyles, improve blood pressure control, and ultimately reduce the risk of future cardiovascular disease (CVD). This randomized controlled trial will assess the impact of SBP PRS disclosure and theory-based genomic counseling on systolic blood pressure and health behaviors. A total of 300 adults aged 18-55 years will be enrolled and randomized to receive either routine clinical care or SBP PRS results with structured genomic counseling based on the Health Belief Model (HBM). Participants will be followed for 12 months. The primary outcome is change in 24-hour mean SBP from baseline to one year. Secondary outcomes include changes in physical activity, diet, medication adherence, smoking, lipid and glucose levels, and body composition. The study will also evaluate how behavior change is influenced by health beliefs, including perceived risk and self-efficacy. This study aims to advance the use of genomic tools in hypertension management and cardiovascular disease prevention.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 21 Apr 2025
- Start date
- 1 Aug 2025
- Primary completion date
- 31 Mar 2030
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- High blood pressure
- NCT number
- NCT06962488
What you commit to
- Study type: Interventional
- Planned participants: 300
- From 1 Aug 2025 to the primary completion date, 31 Mar 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of more than two antihypertensive medication classes.
Other illness
- History of cardiovascular disease, including Myocardial infarction, Angina, Cardiac arrhythmia, Coronary heart disease, Heart failure, Stroke, or transient ischemic attack.
- Significant psychiatric illness (assessed via Global Health Questionnaire-12).
Lab values
- Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² (using CKD-EPI equation).
- Urine albumin-to-creatinine ratio ≥30 mg/g.
- Hepatic transaminase levels \>3× the upper limit of normal.
Other
- Body mass index (BMI) \<18.5 kg/m² or \>45 kg/m².
- Baseline office SBP \>160 mm Hg or DBP \>100 mm Hg.
- Not hypertensive based on 24-hour ABPM (per 2017 ACC/AHA criteria).
- Pregnant or breastfeeding.
- Moderate or severe anxiety (Beck Anxiety Inventory \[BAI\] score \>16).
Who the study is looking for
- Age 18 to 55 years (inclusive) at the time of screening.
- Diagnosis of hypertension defined by 2017 ACC/AHA guidelines, as evidenced by Resting office systolic blood pressure (SBP) of 130-160 mm Hg or Resting office diastolic blood pressure (DBP) of 80-100 mm Hg or Current use of antihypertensive medication.
- Poor cardiovascular health, defined as Life's Essential 8 score \<50.
- Willing and able to undergo 24-hour ambulatory blood pressure monitoring (ABPM) to confirm hypertension.
- Able to provide informed consent.
Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.